These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 29021458)
1. Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections. Tsukagoshi S; Ishizawa K; Hirayanagi K; Nagamine S; Makioka K; Fujita Y; Ikeda Y Intern Med; 2017 Dec; 56(23):3189-3192. PubMed ID: 29021458 [TBL] [Abstract][Full Text] [Related]
2. Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis. Murata S; Aomatsu T; Yoden A; Tamai H Pediatr Int; 2015 Oct; 57(5):942-6. PubMed ID: 25907455 [TBL] [Abstract][Full Text] [Related]
12. Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis. Shima A; Suehiro T; Takii M; Soeda H; Hirakawa M Case Rep Nephrol Dial; 2015; 5(3):187-91. PubMed ID: 26558252 [TBL] [Abstract][Full Text] [Related]
13. [Clinical studies on ceftriaxone in respiratory tract infections. CTRX Study Group]. Shimada K; Kimura H; Kudoh S; Mohri M; Shiraishi T; Amano Y; Kurashima A; Uzawa T; Hisada T; Nagata T Jpn J Antibiot; 1993 Feb; 46(2):184-91. PubMed ID: 8331779 [TBL] [Abstract][Full Text] [Related]
14. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Prince JS; Senac MO Pediatr Radiol; 2003 Sep; 33(9):648-51. PubMed ID: 12830336 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of Endoscopic Managements in Patients with Ceftriaxone-Induced Pseudolithiasis Causing Biliary Obstruction. Doi Y; Takii Y; Ito H; Jingu N; To K; Kimura S; Kimura K; Sanefuji K; Ikeda H; Tachibana S; Otsuka T Case Rep Med; 2017; 2017():3835825. PubMed ID: 29230246 [TBL] [Abstract][Full Text] [Related]
16. [Reversible ceftriaxone-associated biliary pseudolithiasis in three children with renal diseases]. Zhong XH; Chen H; Yao Y; Zhuo XW; Huang JP; Xiao HJ; Ai Y Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):216-9. PubMed ID: 20426960 [TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of ceftriaxone in the treatment of neonatal infections]. Okura K; Yamamoto H; Yamaoka K; Kubo K; Mitsuyoshi I; Haruta T; Kobayashi Y Jpn J Antibiot; 1988 Feb; 41(2):152-64. PubMed ID: 3286924 [TBL] [Abstract][Full Text] [Related]
18. [Single-daily-dose treatment of ceftriaxone for biliary tract infections and bacterial counts in bile]. Tanimura H; Maniwa Y; Okamoto M; Mukaihara S; Takabayashi A; Sato T; Henmi K; Yoshida K; Sawada H Nihon Geka Hokan; 1989 May; 58(3):299-309. PubMed ID: 2619435 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic and clinical evaluations of ceftriaxone in neonates and premature infants]. Motohiro T; Oda K; Aramaki M; Tanaka K; Kawakami A; Shimada Y; Koga T; Tomita S; Sakata Y; Fujimoto T Jpn J Antibiot; 1988 Mar; 41(3):276-305. PubMed ID: 3404647 [TBL] [Abstract][Full Text] [Related]
20. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Starakis I; Karravias D; Asimakopoulos C; Kolaras P; Nikolaidis P; Harlaftis N; Skoutelis A; Bassaris H Int J Antimicrob Agents; 2003 Jan; 21(1):49-57. PubMed ID: 12507837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]